Pharmaceutical Executive Daily: Pfizer Warns Shareholders to Reject Mini-Tender Offer
Share
Subscribe
In today's Pharmaceutical Executive Daily, Pfizer warns shareholders to reject an unsolicited mini-tender offer from Tutanota LLC seeking to purchase up to one million shares at a potentially below-market price, the FDA grants expanded approval to Rhythm Pharmaceuticals' Imcivree as the first approved treatment for acquired hypothalamic obesity, and a new commentary makes the case that AI-powered roleplay data is an untapped source of commercial intelligence for pharma field teams.
